29804 Homepage Banner

Welcome to the Allogeneic Cell Therapies Summit Europe

Allogeneic approaches are deemed the future of cell therapy, due to their potential to reduce costs, increase accessibility and enhance availability. However as clinical readouts emerge, challenges associated with limited durability, disharmonised European regulations and immunogenicity are hindering their efficacies.   

 

The Allogeneic Cell Therapies Summit Europe is returning in January to capture the clinical advances of European drug developers whilst addressing the specific challenges they face in development including European regulatory affairs, donor selection, scalable manufacturing and therapy persistence.   

 

With continued investment and growth in the allogeneic space, join European leaders from Gadeta, Antion Biosciences, TC BioPharm and as well as the US leaders undertaking European trials, such as Atara Bio and Adicet Bio, as they progess development of multiple cell types to produce the next-generation of safe, effective and accessible cell therapies in Europe.

World-Class Speaker Faculty Includes: 

Previously Attending Companies Include:

Our Partners:

25418, Fujifilm Irvine Scientific

Other Events in the Series